Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 21Recruiting 15Completed 6Terminated 4Withdrawn 3Not yet recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 12Gastrointestinal 9Lymphoid 6Plasma cell 3Myeloid 3Head & Neck 3Genitourinary 3Breast 3Sarcoma 2CNS 2Thoracic 1Gynecologic 1

Conditions

Multiple Myeloma 2Leukemia, Plasma Cell 1

Interventions

Dexamethasone 20daratumumab 17Bortezomib 12Lenalidomide 11pomalidomide 8Cyclophosphamide 8Calcium Dobesilate 7belantamab mafodotin 5isatuximab 4fludarabine 4carfilzomib 4Melphalan 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3Biopsy 3tocilizumab 2iberdomide 2Stem Cell Transplantation 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Hyaluronoglucosaminidase 2Fluorodeoxyglucose F18 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2zanubrutinib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Biopsy × Plasma cell × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06948084 2026-05-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Plasma cell

Multiple Myeloma

NCT07463807 2026-05-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
162 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡